Pharmaceutical Products

We strive to address unmet medical needs through excellence in science
At Roche Pharmaceuticals, we focus on finding new medicines that help patients live longer, better lives and evolve the practice of medicine.

Below is a list of Roche medicines that are available in Aotearoa New Zealand. Use the filter function to filter by disease area to find the Data Sheet and Consumer Medicine Information (CMI) for each product. 

If you have a question about a Roche medicine, please

For more information about Roche's Medicines and Cost Share Programmes, Healthcare Professionals can sign up on

Uses of Actemra® (tocilizumab) Infusion:

  • Treatment of moderate to severe rheumatoid arthritis in adults, as well as certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and certain patients with COVID-19.

More Information

Uses of Actemra® (tocilizumab) SC (subcutaneous injection):

  • Treatment of moderate to severe rheumatoid arthritis and giant cell arteritis in adults

More Information


Uses of Alecensa® (alectinib hydrochloride):

  • Treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer.

More Information


Uses of Avastin® (bevacizumab):

  • Treatment of advanced (metastatic) bowel, kidney, breast, brain, lung, ovarian and cervical cancers

More Information


Uses of CellCept® (mycophenolate mofetil):

  • Treatment to prevent rejection of transplanted organs

More Information


Uses of Columvi ® (glofitamab):

  • Columvi® has provisional consent. Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

More Information


Uses of Cotellic® ® (cobimetinib):

  • Treatment of advanced (metastatic) melanoma

More Information


Uses of Erivedge ® (vismodegib):

  • Treatment of advanced (metastatic) basal cell carcinoma

More Information


Uses of Esbriet ® (pirfenidone):

  • Treatment of Idiopathic Pulmonary Fibrosis (IPF)

More Information


Uses of Evrysdi ® (risdiplam):

  • Treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older.

More Information


Uses of Gazyva ® (obinutuzumab):

  • Treatment of previously untreated chronic lymphocytic leukaemia (CLL) and indolent non hodgkin lymphoma (iNHL)

More Information


Uses of Hemlibra ® (emicizumab):

  • Treatment of congenital haemophilia A with or without factor VIII inhibitors

More Information


Uses of Herceptin ® (trastuzumab) SC (subcutaneous injection):

  • Treatment of HER2-positive early and metastatic breast cancer

More Information


Uses of Herceptin ® (trastuzumab) IV:

  • Treatment of HER2-positive early and metastatic breast cancer and for HER2-positive advanced gastric cancer.

More Information


Uses of Kadcyla ® (trastuzumab emtansine):

  • For the second-line treatment of HER2-positive metastatic breast cancer and adjuvant treatment in early HER2-positive breast cancer.

More Information


Uses of Mabthera RA ® (rituximab):

  • Treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis

More Information

Uses of Madopar ® (levodopa and benserazide):

  • Treatment of Parkinson’s disease

More Information


Uses of NeoRecormon ® (epoetin beta):

  • Treatment of anaemia

More Information


Uses of Ocrevus ® (ocrelizumab):

  • Treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)

More Information


Uses of Perjeta ® (pertuzumab):

  • Treatment of HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant) and advanced (metastatic) breast cancer

More Information


Uses of Phesgo (trastuzumab+pertuzumab):

  • For the treatment of HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy.

More Information

Consumer Medicine Information 

Data Sheet

Uses of Polivy (polatuzumab vedotin):

  • For the treatment of certain patients with diffuse large B-cell lymphoma

More Information


Uses of Pulmozyme ® (dornase alfa):

  • Treatment of cystic fibrosis

More Information


Uses of ROZLYTREK ® (entrectinib):

  • Treatment of ROS1 positive locally advanced and metastatic non-small cell lung cancer

  • Treatment of NTRK-fusion positive locally advanced and metastatic solid tumours

More Information


Uses of Tamiflu ® (oseltamivir):

  • Treatment of influenza

More Information


Uses of Tecentriq ® (atezolizumab):

  • Treatment of early and metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic urothelial carcinoma, unresectable hepatocellular carcinoma, and metastatic triple-negative breast cancer.

More Information


Uses of VABYSMO® (faricimab):

  • Treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).

More Information


Uses of Zelboraf ® (vemurafenib):

  • Treatment of advanced (metastatic) melanoma

More Information


Uses of Actemra® (tocilizumab) Infusion:

  • Treatment of moderate to severe rheumatoid arthritis in adults, as well as certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and certain patients with COVID-19.

More Information

Uses of Actemra® (tocilizumab) SC (subcutaneous injection):

  • Treatment of moderate to severe rheumatoid arthritis and giant cell arteritis in adults

More Information


Uses of Mabthera RA ® (rituximab):

  • Treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis

More Information


Uses of Columvi ® (glofitamab):

  • Columvi® has provisional consent. Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

More Information


Uses of Gazyva ® (obinutuzumab):

  • Treatment of previously untreated chronic lymphocytic leukaemia (CLL) and indolent non hodgkin lymphoma (iNHL)

More Information


Uses of Hemlibra ® (emicizumab):

  • Treatment of congenital haemophilia A with or without factor VIII inhibitors

More Information


Uses of Polivy (polatuzumab vedotin):

  • For the treatment of certain patients with diffuse large B-cell lymphoma

More Information


Uses of VABYSMO® (faricimab):

  • Treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).

More Information


Uses of Evrysdi ® (risdiplam):

  • Treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older.

More Information


Uses of Madopar ® (levodopa and benserazide):

  • Treatment of Parkinson’s disease

More Information


Uses of Ocrevus ® (ocrelizumab):

  • Treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)

More Information


Uses of Alecensa® (alectinib hydrochloride):

  • Treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer.

More Information


Uses of Avastin® (bevacizumab):

  • Treatment of advanced (metastatic) bowel, kidney, breast, brain, lung, ovarian and cervical cancers

More Information


Uses of Cotellic® ® (cobimetinib):

  • Treatment of advanced (metastatic) melanoma

More Information


Uses of Erivedge ® (vismodegib):

  • Treatment of advanced (metastatic) basal cell carcinoma

More Information


Uses of Herceptin ® (trastuzumab) SC (subcutaneous injection):

  • Treatment of HER2-positive early and metastatic breast cancer

More Information


Uses of Herceptin ® (trastuzumab) IV:

  • Treatment of HER2-positive early and metastatic breast cancer and for HER2-ve advanced gastric cancer.

More Information


Uses of Kadcyla ® (trastuzumab emtansine):

  • For the second-line treatment of HER2-positive metastatic breast cancer and adjuvant treatment in early HER2-positive breast cancer.

More Information


Uses of Perjeta ® (pertuzumab):

  • Treatment of HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant) and advanced (metastatic) breast cancer

More Information


Uses of Phesgo (trastuzumab+pertuzumab):

  • For the treatment of HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy.

Uses of ROZLYTREK ® (entrectinib):

  • Treatment of ROS1 positive locally advanced and metastatic non-small cell lung cancer

  • Treatment of NTRK-fusion positive locally advanced and metastatic solid tumours

More Information


Uses of Tarceva ® (erlotinib):

  • Treatment of locally advanced or metastatic non-small cell lung cancer

More Information


Uses of Tecentriq ® (atezolizumab):

  • Treatment of early and metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic urothelial carcinoma, unresectable hepatocellular carcinoma, and metastatic triple-negative breast cancer.

More Information


Uses of Zelboraf ® (vemurafenib):

  • Treatment of advanced (metastatic) melanoma

More Information


Uses of Esbriet ® (pirfenidone):

  • Treatment of Idiopathic Pulmonary Fibrosis (IPF)

More Information


Uses of NeoRecormon ® (epoetin beta):

  • Treatment of anaemia

More Information


Uses of Pulmozyme ® (dornase alfa):

  • Treatment of cystic fibrosis

More Information


Uses of CellCept® (mycophenolate mofetil):

  • Treatment to prevent rejection of transplanted organs

More Information


Uses of Tamiflu ® (oseltamivir):

  • Treatment of influenza

More Information


The promotion and sale of pharmaceutical and diagnostics products is highly regulated. Roche has a strong commitment to comply with all applicable laws, regulations and industry codes.

In New Zealand our business practices are regulated and guided by the following Acts and Codes.

  • The and


Our Code of Conduct also guides our business practices.

Discover more

Our Code of ConductHealthcare Professionals Portal

© 2024, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.

M-NZ-00000625-v12.0/MR10379/MAY24. This site was last updated JUN2024

ContactDrug SafetyWorldwide LocationslinkedinfacebooktwitterinstagramyoutubePharma solutionsRoche careersRoche cancer treatmentsRoche diagnosticsRoche hubPrivacy statementLegal statementContact UsHealthcare Professionals Portal